Envíos recientes

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

Schmierer, Klaus; Wiendl, Heinz; Barkhof, Frederik; Achiron, Anat; Derfuss, Tobias; Montalban, Xavier (SAGE Publications, 2025-01)

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression

Sanchis, Pablo Antonio; Sabater, Agustina; Lechuga, Julia; Rada, Jimena; Seniuk, Rocio; Pascual, Gaston Mario; Anselmino, Nicolas; Mateo, Joaquin (Springer Nature, 2025-10-07)

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity

He, Bo; Wood, Kira Hope; Li, Zhi-jie; Ermer, Judith Anna; Li, Ji; Bastow, Edward; Oliveira, Mafalda (EMBO Press, 2025-05)

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Bergmann, Lothar; ALBIGES, Laurence; Ahrens, Marit; Gross-Goupil, Marine; Boleti, Ekaterini; Gravis, Gwenaelle; Suárez, Cristina (Elsevier, 2025-07)

Final 5-year outcomes of the Epic02 – RANGO study: A real-world registry of the durable fluoroacrylate polymer-based sirolimus-eluting Angiolite® stent

Perez de Prado, Armando; Bayón, Jeremías; Sánchez Pérez, Ignacio; Aguar Carrascosa, Pablo; Rodrigues, Alberto; moreu, jose; García del Blanco, Bruno (Elsevier, 2025-07)

Scientia. Depósito de Información Digital del Departamento de Salud

HVH - Articles científics: Envíos recientes

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Final 5-year outcomes of the Epic02 – RANGO study: A real-world registry of the durable fluoroacrylate polymer-based sirolimus-eluting Angiolite® stent

Scientia. Depósito de Información Digital del Departamento de Salud

HVH - Articles científics: Envíos recientes

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study ﻿

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression ﻿

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity ﻿

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial ﻿

Final 5-year outcomes of the Epic02 – RANGO study: A real-world registry of the durable fluoroacrylate polymer-based sirolimus-eluting Angiolite® stent ﻿

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study

PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression

Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Final 5-year outcomes of the Epic02 – RANGO study: A real-world registry of the durable fluoroacrylate polymer-based sirolimus-eluting Angiolite® stent